Maxim Group Cuts Oncolytics Biotech (NASDAQ:ONCY) Price Target to $3.00

Oncolytics Biotech (NASDAQ:ONCY) had its target price trimmed by Maxim Group from $5.00 to $3.00 in a research report released on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms have also issued reports on ONCY. Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th. Royal Bank of Canada reduced their target price on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Oncolytics Biotech in a report on Monday. Finally, Leede Financial lowered shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th. Three equities research analysts have rated the stock with a buy rating, According to MarketBeat, Oncolytics Biotech has an average rating of “Buy” and a consensus target price of $4.00.

Oncolytics Biotech Stock Performance

Shares of ONCY stock opened at $0.63 on Monday. The firm has a market cap of $53.87 million, a P/E ratio of -2.33 and a beta of 1.18. Oncolytics Biotech has a one year low of $0.58 and a one year high of $1.53. The firm’s 50 day moving average price is $0.77 and its 200-day moving average price is $0.92.

Institutional Investors Weigh In On Oncolytics Biotech

A number of large investors have recently modified their holdings of ONCY. Vantage Point Financial LLC purchased a new stake in shares of Oncolytics Biotech in the 4th quarter valued at approximately $27,000. National Bank of Canada FI increased its position in shares of Oncolytics Biotech by 199.6% in the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock valued at $60,000 after purchasing an additional 42,955 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Oncolytics Biotech by 59.6% in the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after buying an additional 24,997 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Oncolytics Biotech in the 4th quarter valued at $90,000. Finally, International Assets Investment Management LLC grew its position in shares of Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock valued at $186,000 after buying an additional 26,069 shares during the last quarter. 6.82% of the stock is owned by hedge funds and other institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.